Boostrix: all 28 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)Not yet recruitingNCT07492303Phase 1
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in PregnancyRecruitingNCT07097012Phase 4
- A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of AgeCompletedNCT05169905Phase 3Results posted
- Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai WomenCompletedNCT03498300Early Phase 1Results posted
- Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian SubjectsCompletedNCT03311659Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant WomenCompletedNCT02377349Phase 4Results posted
- Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and OlderCompletedNCT02052596Phase 3Results posted
- Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese ChildrenCompletedNCT01988857Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of AgeCompletedNCT01767376Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedNCT01755689Phase 3Results posted
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young AdultsCompletedNCT01738477Phase 3Results posted
- Evaluation of Boostrix™10 Years After Previous Booster VaccinationCompletedNCT01147900Phase 4Results posted
- Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.CompletedNCT00835237Phase 3Results posted
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058CompletedNCT00548171Phase 4Results posted
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsCompletedNCT00518180Phase 3Results posted
- Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsCompletedNCT00385255Phase 3Results posted
- Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsCompletedNCT00346073Phase 3Results posted
- Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®CompletedNCT00319553Phase 4Results posted
- US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseaseCompletedNCT00282295Phase 4Results posted
- GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of AgeWithdrawnNCT06494475Phase 2/3
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)TerminatedNCT05543642Phase 4
- Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune ResponsesCompletedNCT02555540Phase 4
- A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' AssaysCompletedNCT02072525Phase 4
- Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)CompletedNCT01294605Phase 4
- Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®CompletedNCT01277705Phase 3
- Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.TerminatedNCT00544271Phase 4
- Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT VaccineCompletedNCT00452686Phase 3
- Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.CompletedNCT00406562Phase 3